GlassScriptPhysician profile
Herbert D Alexander
NPI 1093992588
$5,644.95
in general payments reported to CMS, 2019-2025
31 companies · $915 in 2025
The $915 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $863 · 2021: $719 · 2022: $813 · 2023: $398 · 2024: $908 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,832 · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.66 |
| Education | $389.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $935.92 | 2019-2025 | Rinvoq |
| Leo Pharma INC. | $615.38 | 2019-2023 | Adbry |
| Janssen Biotech, INC. | $478.61 | 2021-2025 | Tremfya |
| Genzyme Corporation | $454.07 | 2019-2025 | |
| Galderma Laboratories, L.P. | $397.95 | 2019-2025 | Nemluvio, Aklief |
| Allergan, INC. | $355.65 | 2019-2022 | |
| Incyte Corporation | $325.73 | 2022-2023 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $323.38 | 2019-2024 | Jublia |
| Almirall LLC | $233.64 | 2019-2023 | Seysara |
| Regeneron Healthcare Solutions, INC. | $206.15 | 2020-2022 | |
| Ucb, INC. | $184.16 | 2019-2025 | Bimzelx |
| Pfizer INC. | $165.22 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $162.72 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $104.92 | 2021-2025 | Winlevi, Absorica Ld |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $92.30 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $67.73 | 2022-2023 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $64.10 | 2024-2025 | |
| Vyne Pharmaceuticals INC. | $61.57 | 2020 | |
| Mayne Pharma Commercial LLC | $54.05 | 2020-2023 | |
| Merz North America, INC. | $48.31 | 2019 | |
| Sandoz INC. | $37.99 | 2020-2021 | |
| Epi Health, LLC | $35.49 | 2019-2020 | |
| Botanix Sb INC | $34.56 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.27 | 2024 | |
| Fidia Pharma USA INC. | $17.63 | 2024 | |
| Celgene Corporation | $15.95 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.77 | 2019 | |
| Lilly USA, LLC | $14.43 | 2021 | |
| Dermavant Sciences, INC. | $12.98 | 2023 | Vtama |
| Merck Sharp & Dohme LLC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.